Announcement on Litigation Results of the Company
Filed with SSE · · 2 pages · Chinese
Beijing Sun-Novo Pharmaceutical Research Co. Ltd. on 6ix
Earlier from Beijing Sun-Novo Pharmaceutical Research
- Announcement on Stock Repurchase, Shareholding Increase and Loan Extension
- Announcement on Deferring the Reply to the "Inquiry Letter Regarding the Review of Beijing Sun-Novo Pharmaceutical Research Co.,Ltd.’s Share Issuance and Convertible Bond Issuance for Asset Acquisition and Raising of Supporting Funds, and Related Party Transaction"
- Announcement on Signing the Technology Development Agreement for STC008 Injection
- Announcement on Voluntary Disclosure of Co-Establishment of a Joint Laboratory
- Announcement on Resolutions of the 5th Extraordinary General Meeting in 2025
Later from Beijing Sun-Novo Pharmaceutical Research
- Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Application for ABA001 Injection
- Announcement on Terminating the Issuance of Shares and Convertible Corporate Bonds to Purchase Assets and Raising Supporting Funds and Related Party Transactions, and the Withdrawal of Application Documents
- Announcement on Progress in Litigation Involved by the Company
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Cooperative Investment with Private Fund
Follow Beijing Sun-Novo Pharmaceutical Research into a list and get an email when it puts out news.
Follow Beijing Sun-Novo Pharmaceutical Research